Adagio Therapeutics, Inc. (ADGI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADGI Stock Price Chart Interactive Chart >
ADGI Price/Volume Stats
| Current price | $2.98 | 52-week high | $78.82 |
| Prev. close | $2.70 | 52-week low | $2.46 |
| Day low | $2.65 | Volume | 887,800 |
| Day high | $3.00 | Avg. volume | 3,354,358 |
| 50-day MA | $3.41 | Dividend yield | N/A |
| 200-day MA | $17.46 | Market Cap | 326.95M |
Adagio Therapeutics, Inc. (ADGI) Company Bio
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.
Latest ADGI News From Around the Web
Below are the latest news stories about Adagio Therapeutics Inc that investors may wish to consider to help them evaluate ADGI as an investment opportunity.
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive OfficerWALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the company’s Board of Directors has appointed David Hering interim chief executive officer, effective immediately. Mr. Hering, who will also remain the company’s chief operating officer, succeeds Tillman G |
Adagio Lays Out Development Plans For COVID-19-Focused ADG20 ProgramAdagio Therapeutics Inc (NASDAQ: ADGI) has outlined strategic initiatives for its ADG20 program and research efforts to address SARS-CoV-2 and other coronaviruses. ADG20 is an investigational monoclonal antibody (mAb) being developed to prevent and treat COVID-19. Adagio plans to analyze clinical data from its global Phase 2/3 clinical trials for the prevention (EVADE study) and treatment (STAMP study) of COVID-19 to assess the preliminary safety and efficacy of ADG20 at the 300mg dose in each t |
Adagio CEO Gerngross to exit Covid antibody company he foundedAdagio Therapeutics Inc. CEO Tillman Gerngross is stepping away from the startup he founded as the drugmaker works to determine just how effective its Covid-19 antibodies are against the omicron variant of the coronavirus. |
Adagio Therapeutics Announces ADG20 Development Plans and Pipeline UpdatesMultiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of Antibodies in Response to Continuously Emerging SARS-CoV-2 Variants WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases w |
Adagio Therapeutics Announces CEO Succession PlanWALTHAM, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a Chief Executive Officer succession plan. Current Adagio CEO Tillman Gerngross, Ph.D. has communicated to the Chairperson of the Board of Directors of Adagio that he agreed in principle to resign from his positi |
ADGI Price Returns
| 1-mo | 2.76% |
| 3-mo | -54.36% |
| 6-mo | -93.64% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -58.95% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...